31783 Etanercept in toxic epidermal necrolysis: In support of standard of care

Abstract

Background: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe cutaneous adverse reaction (SCAR) that is a result of an immune-mediated cascade orchestrated by activated cytotoxic T-cells leading to the release of granulysin, perforin, and interferon-gamma. Despite its high morbidity and mortality, there is no established standard of care for the pharmacological management of SJS/TEN patients. The rationale behind use of etanercept, a TNF-alpha inhibitor, has been supported by case reports and small mechanistic studies, though the current literature is limited and dispersed.